北京海纳有容投资管理有限公司(以下简称“海容资本”)是一家专注于医疗健康领域的股权投资管理机构,成立于2012年,总部位于北京。海容资本是中国证券业协会的特别会员 。

      海容资本的创始合伙人分别毕业于中国人民银行研究生部、北京大学、中国人民大学和北京协和医学院等著名学府,既有多年的投资行业从业经验,也有对医疗健康领域的深度理解和敏锐触角。

      海容资本已和医疗健康领域内的优秀企业如亚宝药业、葵花药业、博济医药、天士力、济川药业、威高集团等医药上市公司建立了紧密的战略合作关系,并共同打造一个医疗健康领域的投资、并购及产品运作平台。

      海容资本的核心业务定位于医疗领域初创期风险投资、扩张期成长投资、成熟期并购投资,并可为投资机构、相关企业提供医疗健康等行业的投资咨询服务,同时海容资本依托于在医疗健康领域多年积累的深厚人脉,可以为企业提供专业的医药品种交易、医疗器械咨询、销售团队搭建等方面的服务。

       截止到2019年9月,海容资本已完成投资企业13家(含易明医药(002826.SZ)、亚宝药业(600351.SH)定增、悦康药业、合纵药业、微康生物、康倍得药业(837905.OC)、丹大生物、凡知医学、和鼎医药等,全资收购1家(西藏海容唐果药业有限公司),并在持续追踪数十家医疗健康行业的优秀企业。


       海容资本秉持“依托未来30年全球最大健康消费市场的繁荣,推动医疗技术创新,引领健康行业发展,为投资人带来较低风险下的较高收益。“投资理念,以“专注医疗、创造财富、服务社会”为愿景,通过资本运营和管理提升,和投资企业共同成长,和商业伙伴分享快乐。


    Beijing Hainayourong Investment Management Co., Ltd., commonly referred to as Hairong, is an investment management corporation based in Beijing, China. Founded in 2012, Hairong focus on the asset investment and management in the medical treatment and health field. Also, Hairong is a special member of China Securities Industry Association.

 

    The founders and partners of Hairong graduated from the famous universities in China, like the people’s Bank of China Graduate Student Department, the Beijing University, the Renmin University of China, the China Union Medical College and so on. Because of the higher education and numerous experiences, Hairong always has advance consciousness and deep understand of the medical field.

 

     To build a platform for enterprise’s investment, emerges and acquisitions, and operation, Hairong establishing bonds of cooperation with many outstanding companies in the medical field, such as the Albao Pharmaceutical Industry, Sunflower Pharmaceutical Industry, Guangzhou Boji Medical and Biotechnological Company, and Tianjin Tasly Pharmaceutical Company.

 

    The core business of the Hairong includes venture capital, growth investment, and merger and acquisition. Also, Hairong provides consulting services for the companies and agents that are interested in the medical treatment field. In addition, Hairong can provide the services about the trade of medical, the consultation of equipment, and establishing of sales team.

 

    By the end of December 2019, Hairong had completed 13investments (like Tibet Aim Pharmaceutical Company) include a directional add-issuance (Albao Pharmaceutical Industry), buyout the Xizang Hairong Tangguo Pharmaceutical Company, and follows up many outstanding company.

 

   “By relying on the development of the world's largest health consumer market in the next 30 years, it will promote the innovation of medical technology, lead the development of health industry and bring higher returns to investors at lower risk. " Investment concept, " focusing on medical care, creating wealth, service society "as the vision, through the Hairong’s operation and management promotion, and investment enterprises to grow together, and business partners to share happiness.